J&J: positive results for icotrokinra in psoriasis

(CercleFinance.com) - Johnson & Johnson announces positive results from a Phase 3 study of icotrokinra (JNJ-2113) for patients aged 12 and over with moderate to severe plaque psoriasis.


The study met its primary endpoints, with 64.7% of patients achieving clear or almost clear skin and 49.6% achieving a 90% reduction in PASI (Psoriasis Area and Severity Index) at 16 weeks, compared with 8.3% and 4.4% for placebo. These rates continued to increase at 24 weeks.

Safety data were consistent with previous studies, with a similar frequency of adverse events between icotrokinra and placebo.

Further results will be presented shortly.

Icotrokinra could meet patients' needs with daily oral therapy, it said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.